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ABSTRACT
High-dose immunosuppressive therapy and autologous
stem cell transplantation (commonly referred to as ‘‘stem
cell transplantation’’) is an established treatment for a
variety of haemato-oncological conditions. Recent studies
have confirmed its potent clinical and immunological
effects in rheumatic autoimmune diseases, including
severe diffuse systemic sclerosis (SSc). With modifica-
tions of treatment protocols and more stringent selection
of patients, the safety profile of stem cell transplantation
has improved as expressed in lower treatment-related
morbidity and mortality. Prospective, randomised trials are
in progress in Europe and North America to compare the
safety and efficacy of stem cell transplantation with
conventional chemotherapy in patients with early diffuse
SSc, on the premise that induction of remission in early
disease can be achieved by stem cell transplantation as a
means to interrupt fibrogenesis.
Systemic sclerosis (SSc) is a complex connective
tissue disease characterised by clinical and labora-
tory features of vasculopathy, fibrosis, inflamma-
tion and autoimmunity. Two subsets can be
identified—limited and diffuse SSc. Quality of life
and functional ability in most patients are
impaired owing to Raynaud’s disease, skin thicken-
ing and contractures. Patients with the diffuse
subset and organ involvement, in particular, are at
high risk of early mortality, with 5-year survival
rates comparable with patients with lymphoma.
While the aetiology of SSc is unknown, sig-
nificant progress has been made in elucidating
some of the pathogenetic mechanisms involved in
SSc (reviewed by Denton and Black1). Skin speci-
mens from patients with early SSc contain mono-
nuclear inflammatory infiltrates, whereas those of
patients with advanced disease tend to be more
fibrotic. This observation and experimental studies
are in keeping with the hypothesis that fibroblasts
are activated by (autoreactive?) T and B lympho-
cytes, leading to formation of myofibroblasts and
excessive matrix production in skin and internal
organs. Vascular symptoms due to vasculopathy
universally precede the other manifestations of SSc
and it is thought that the repetitive or persistent
local release of oxygen radicals is a key event in the
transformation of the stromal cell compartment.
Cross talk between cells is in part mediated by
cytokines, some of which are dysregulated in SSc—
for example, interleukin (IL)6, IL4, transforming
growth factor (TGF)b.
A recent study on CTGF polymorphism under-
lined the role of genetic factors (and cytokines) in
the predisposition to develop SSc.2 Nevertheless,
treatment with an anti-TGFb monoclonal
antibody was ineffective in a controlled, double-
blind study.3 Of all other treatments investigated
in SSc so far, only cyclophosphamide-based regi-
mens have shown a consistent, but modest, benefit
on skin thickening and lung involvement, waning
after discontinuation of treatment.4 No treatment
has proved to be effective in improving long-term
outcome, as testament to the huge unmet need in
this disease. In part, this may be attributed to
inclusion in trials of patients with end-stage SSc,
not amenable to disease-modifying treatment. For
example, serial lung function studies in patients
with SSc have shown that the greatest decline in
lung function occurs in the first 4 years.5 Based on
these and other available clinical data, early SSc
could provide a brief opportunity to evaluate the
disease-modifying properties of new treatments.
Stem cell transplantation (SCT) is the short
name for a multistep treatment aimed at resetting
of the immune system by high-dose immuno-
suppressive treatment (HDIT) combined with
SCT. Its introduction in the field of autoimmune
disease in the mid-1990s built on extensive
experience in haemato-oncology of treating malig-
nant diseases with (non)myeloablative condition-
ing and allogeneic or autologous bone marrow
transplantation. Early pioneering work by the
Seattle transplant team had shown that a small
proportion of patients with leukaemia survived
after allogeneic bone marrow transplantation,
showing its curative potential.6 With better selec-
tion of patients and adaptations of transplant
protocols, treatment-related toxicity and mortality
was reduced and long-term survival improved.
Treatment-related mortality of autologous and
allogeneic stem cell transplantation generally is
below 5% and 15%, respectively, for most indica-
tions now.
The therapeutic potential of HDIT + SCT in
autoimmune disease was first seen in patients with
rheumatoid arthritis (RA) treated with allogeneic
bone marrow transplantation for gold-induced
aplastic anaemia. These clinical observations were
corroborated by studies in several animal models of
experimental autoimmune disease (reviewed by
Van Bekkum7). These models were instrumental in
identifying the optimal transplant regimen to
induce remission. Although these conditions dif-
fered slightly between disease models, the principle
that HDIT + SCT can cure autoimmune disease
was firmly established. Of note, autologous SCT
proved as effective as allogeneic SCT in some
models, thus paving the way for its application in
human autoimmune disease.
A multidisciplinary Working Party on
Autoimmune Diseases was founded by the
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European Blood and Marrow Transplant/European League
Against Rheumatism (EBMT/EULAR), which issued guidelines
for patient eligibility criteria and transplant protocols and set up
a registry to collect data from transplanted cases in Europe. A
subsequent retrospective analysis of registry data from 473
patients and data from a number of pilot studies confirmed the
feasibility of SCT in autoimmune diseases.8 Interestingly, the
probability of disease progression, overall survival and treat-
ment-related mortality appeared dependent on conditioning
intensity and underlying disease, with the highest survival and
lowest treatment-related mortality in RA and lowest survival
and highest treatment-related mortality in SSc and systemic
lupus erythematosus (SLE), probably reflecting their severity
and extent of internal organ involvement. With time and
experience, the risks of HSCT have decreased significantly, as
illustrated by the gradual drop in transplant-related mortality
from 17% in the first cohort of 41 patients with SSc from the
(EBMT/EULAR) registry to 8.7% in a subsequent analysis of 65
patients (which included the 41 first cohort patients).9 10
To overcome the limitations of registry analyses, a recent
study focused on 26 patients with SSc in the Netherlands and
France treated with a uniform protocol based on high-dose
cyclophosphamide and CD34 selection of autologous grafts
with similar eligibility criteria, outcome measures and trans-
plant regimen.11 With a median follow-up of 5.3 years (range 1–
7.5), the Kaplan–Meier estimated survival at 7 years was 84.8%
(95% CI 70.2% to 100%) and event-free survival, defined as
survival without mortality, relapse or progression of SSc
resulting in major organ dysfunction, was 57.1% (95% CI
39.3% to 83%). Two patients died from disease relapse, one
from malignancy. Several infectious complications occurred,
including three cases of reactivation of herpes zoster and two
with atypical mycobacteria, but all resolved with treatment. In
line with earlier observations, a more than 50% reduction in
skin thickening was observed from baseline in the group as a
whole (p,0.001), while pulmonary, renal and cardiac function
remained stable in most patients. The most striking finding was
the improvement of performance status (0 normal, 4 bedridden)
from 2.21 at baseline to 0.6 at 5 years (p,0.05).
Similar data were obtained in the long-term follow-up study
of 27 patients with SSc in North America using a transplant
regimen which included total body irradiation (800 cGy) with
lung shielding, cyclophosphamide (120 mg/kg) and equine
antithymocyte globulin (90 mg/kg), followed by CD34-selected
haematopoietic cell transplantation.12 Seventeen of 27 (63%)
evaluable patients who survived at least 1 year after HDIT had
sustained responses at a median follow-up of 4 years (range 1–
8). Skin thickening as assessed by the modified Rodnan skin
score and functional ability as determined by the modified
Health Assessment Questionnaire Disability Index improved
significantly at final evaluation. Skin biopsies confirmed a
Box 1 End points of the ASTIS trial
Primary end points
The primary end point of the ASTIS-trial is event-free survival.
Event-free survival is defined as the time in days from the day of
randomisation until the occurrence of death due to any cause or
the development of persistent major organ failure (heart, lung,
kidney) defined as follows:
c Heart: left ventricular ejection fraction ,30% by multigated
radionuclide angiography (MUGA) (or cardiac echo);
c Lungs: respiratory failure—that is, resting arterial oxygen
tension (PaO2) ,8 kPa (,60 mm Hg) or resting arterial
carbon dioxide tension (PaCO2) .6.7 kPa (.50 mm Hg), or
both, without oxygen supply;
c Kidney: need for renal replacement therapy.
Secondary end points
The major secondary end points of the study are treatment-
related mortality, treatment toxicity and progression-free survival,
defined as the time in days since the day of randomisation until
any of the following changes from baseline has been documented
at two consecutive 3-month evaluations:
c death,
c 10% drop in (forced) vital capacity or > 15% drop in carbon
monoxide transfer factor (of predicted values), or both,
c 15% drop in left ventricular ejection fraction by echo or MUGA,
c 15% drop in body weight,
c 30% drop in creatinine clearance,
c 30% increase in skin score,
c 0.5 increase in Scleroderma Health Assessment Questionnaire.
Box 2 ASTIS trial: inclusion criteria
c Age between 18 and 65 years;
c Established diagnosis of systemic sclerosis according to
American Rheumatism Association criteria;
c Diffuse scleroderma with disease duration either: (a) (2
years since development of first sign of skin thickening plus
modified Rodnan skin score >20 plus involvement of trunk
plus erythrocyte sedimentation rate .25 mm/1st h and/or
haemoglobin ,110 g/l, not explained by causes other than
active scleroderma, or (b) born (4 years since development
of first sign of skin thickening plus modified Rodnan skin score
>15 plus major organ involvement (with documented
evidence of onset or clinically significant worsening in the
previous 6 months) as defined by one of:
– Respiratory involvement—that is, carbon monoxide
transfer factor and/or (forced) vital capacity ( 80% (of
predicted) and evidence of interstitial lung disease (chest
x ray and/or high-resolution CT scan and/or
bronchoalveolar lavage and/or biopsy of the lungs) with
clinically relevant obstructive disease and emphysema
excluded;
– Renal involvement—that is, any of the following criteria:
hypertension (two successive blood pressure readings of
either systolic pressure >160 mm Hg or diastolic
pressure >110 mm Hg, at least 12 h apart), persistent
urine analysis abnormalities (proteinuria, haematuria,
casts), microangiopathic haemolytic anaemia, new renal
insufficiency (serum creatinine greater than the upper
limit of normal); non-scleroderma-related causes (eg,
medication, infection, etc) must have been reasonably
excluded;
– Cardiac involvement—that is, any of the following
criteria: reversible congestive heart failure, atrial or
ventricular rhythm disturbances such as recurrent
episodes of atrial fibrillation or flutter, recurrent atrial
paroxysmal tachycardia or ventricular tachycardia,
second- or third-degree atrioventricular block, pericardial
effusion; non-scleroderma related causes must have been
reasonably excluded by an experienced cardiologist;
c Informed consent.
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significant decrease of dermal fibrosis compared with baseline
(p,0.001). Lung, heart and kidney function remained clinically
stable. There were 12 deaths during the study (eight transplan-
tation-related; four SSc-related). The estimated progression-free
survival was 64% at 5 years. The observed sustained responses
exceeded those previously reported with other treatments.
Based on these encouraging results prospective, multicentre
trials have been launched in Europe and the United States to
investigate further the therapeutic value of HDIT + SCT in SSc
and other autoimmune diseases. The first of these, the ASTIS
trial (Autologous Stem cell Transplantation International
Scleroderma trial), started in 2001 under the auspices of the
EBMT/EULAR to compare the safety and efficacy of HSCT
with that of conventional pulse therapy cyclophosphamide in
patients with severe SSc at risk of early mortality. Box 1 lists the
study end points of the ASTIS trial. Eligibility criteria include a
diagnosis of diffuse systemic sclerosis of recent onset and major
organ (heart, kidney, lungs) involvement according to pre-
defined criteria (box 2). Of note, patients who have been
extensively pretreated with cyclophosphamide are excluded, as
are patients with severe pulmonary hypertension who are at
risk of fluid overload (box 3). Figure 1 shows details of both
treatments.
At the time of writing this article (July 2008), 123 patients
from 25 centres in 10 countries had been randomised to either
HSCT (n = 66) or to the control arm (n = 57) with a median
follow-up of 30 months. The majority of patients were enrolled
because of new or progressive lung disease. Interim safety
analyses are done regularly, which have led to adjustments of
the protocol (eg, administration of antithymocyte globulin).
The North American counterpart of the ASTIS trial, sponsored
Box 3 ASTIS trial: exclusion criteria
c Pregnancy or unwillingness to use adequate contraception
during study;
c Concomitant severe disease:
– Respiratory—that is, mean pulmonary arterial pressure
.50 mm Hg (by cardiac echo or right heart
catheterisation), carbon monoxide transfer factor ,40%
predicted, respiratory failure as defined by the primary
end point;
– Renal—that is, creatinine clearance ,40 ml/min
(measured or estimated);
– Cardiac—that is, clinical evidence of refractory
congestive heart failure; left ventricular ejection fraction
,45% by multigated radionuclide angiography or cardiac
echo; chronic atrial fibrillation necessitating oral
anticoagulation; uncontrolled ventricular arrhythmia;
pericardial effusion with haemodynamic consequences as
evaluated by an experienced echocardiographist;
– Liver failure as defined by a sustained threefold increase
in serum transaminase or bilirubin;
– Psychiatric disorders including active drug or alcohol
abuse;
– Concurrent neoplasms or myelodysplasia;
– Bone marrow insufficiency defined as leucocytopenia
,4.06109/l, thrombocytopenia ,506109/l, anaemia
,80 g/l, CD4+ T lymphopenia ,2006106/l;
– Uncontrolled hypertension;
– Uncontrolled acute or chronic infection, including HIV,
human T-lymphotropic virus-1, 2 positivity;
c Previous treatments with total lymphoid irradiation, total body
irradiation or alkylating agents including cyclophosphamide
(.5 g IV cumulative, or .3 months oral up to 2 mg/kg body
weight);
c Significant exposure to bleomycin, tainted rapeseed oil, vinyl
chloride; trichloroethylene or silica; eosinophilic myalgia
syndrome; eosinophilic fasciitis;
c Poor compliance of the patient as assessed by the referring
doctors.
Figure 1 Treatment arms of the ASTIS trial. ATG, antithymocyte
globulin; G-CSF, granulocyte-colony stimulating factor.
Figure 2 Normalisation of nailfold capillaroscopy pattern in a patient
with systemic sclerosis treated with high-dose immunosuppressive
therapy and autologous stem cell transplantation.
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by the National Institutes of Health—the ‘‘Scleroderma:
Cyclophosphamide Or Transplantation (SCOT) trial’’—com-
pares safety and efficacy of a different transplant regimen with
intravenous pulse therapy cyclophosphamide. The protocols of
the ASTIS and SCOT trials are matched with respect to entry
criteria, study parameters, end points and the control arm to
facilitate future analyses. Long-term follow-up of patients from
these trials is crucial in order to monitor potentially late
sequelae or discover delayed diverging trends in (event-free)
survival.
The observations of profound clinical effects of HDIT + SCT
in autoimmune disease, including SSc, are in essence largely
empirical. Although comprehensive translational studies are
scarce, evidence is emerging that clinical events are paralleled by
fundamental alterations of the immune system: induction of
regulatory T cells (juvenile idiopathic arthritis), capillary
regeneration (SSc) (fig 2), restoration of T-cell repertoire
(multiple sclerosis, SLE), elimination of autoantibody-producing
cells (RA, SLE) and remodelling of fibrosis (SSc).13–19
Nevertheless, the relationship between clinical outcome and
immune effects is complex, as shown by the persistence of T-
cell receptor abnormalities and autoantibodies in transplanted
patients with SSc.20
Stem cell transplantation has evolved into an established
treatment for patients with severe rheumatic autoimmune
disease, including patients with diffuse SSc at risk of premature
mortality. Treatment-related toxicity is significant, however,
and whether the benefits of this new treatment modality
outweigh the risks can only be determined through prospective
randomised trials, such as the ASTIS and SCOT trials.
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